Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
158
resultados
Última actualización
01/03/2026 [07:23:00]
Resultados 125 a 150 de 158
Resumen de: US20260008840A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: US20260011407A1
The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of biomarkers in such patients allows identification of those patients who will respond to LRRK2 inhibitors. Thus, the invention provides methods of identifying PD patients who will respond to LRRK2 inhibitors and methods of treating such patients.
Resumen de: US20260007635A1
Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).
Resumen de: US20260007706A1
The present disclosure provides methods and compositions for the treatment of Alzheimer's disease. The methods and compositions of the present disclosure comprise AAV vectors and AAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for an APOE2 polypeptide.
Resumen de: US20260008771A1
Pyridazine based compounds and pharmaceutical compositions that may be used for treating synaptic and behavioral dysfunction such as that associated with Alzheimer's Disease, tauopathies, Alzheimer's Disease related dementia, and other dementia. Compounds disclosed herein can be used for treatment of neuropsychiatric, cognitive or behavioral disorders, especially those associated with neurodegenerative disorders. Also disclosed is a method for treating neuropsychiatric, cognitive or behavioral disorders in a subject suffering from a neurodegenerative disease by administering these compounds and pharmaceutical compositions to a subject in need thereof.
Resumen de: US20260009082A1
Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's disease, cardiovascular disease, arthritis, and adverse pregnancy outcomes. The devices, kits, and methods utilize an analysis of single nucleotide polymorphisms (SNPs) from various interleukins.
Resumen de: WO2026006909A1
The present application relates to treatment of Alzheimer's disease. More specifically, the present application relates to a method for treating, palliating or preventing progression of Alzheimer's disease in a subject in need thereof, or improving cognition, suicidality, behavioral disturbance, clinical global impression, and/or functional ability in a subject with Alzheimer's disease, or improving global cognition, the method comprising administering to the subject at least about 50 mg of Montelukast daily, wherein the Montelukast is formulated as an oral dosage film for oral administration.
Resumen de: AU2024305538A1
The present disclosure provides methods of differentiating pluripotent stem cells, including induced pluripotent stem cells, into lineage-specific floor plate midbrain progenitor cells, determined dopaminergic neuronal progenitor cells, committed dopaminergic neuronal progenitor cells and/or dopaminergic neuronal cells. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease, and articles of manufacture and kits for use thereof.
Resumen de: WO2026010936A1
Provided herein are compositions, including epitope megapools, and methods for detecting the presence of: a neurodegenerative disorder-associated or an immune response relevant to a neurodegenerative disorder including T cells responsive to one or more Neurodegenerative disease-associated peptides or proteins, fusion protein, a pool of two or more peptides, a polynucleotide encoding the same comprising, consisting of, or consisting essentially of: one or more amino acid sequences of a target set forth SEQ ID NOS: 1 to 123, Table 1, or Table 2. The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.
Resumen de: WO2026010789A1
This disclosure provides compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, e.g., R1-R6, L, and W are defined herein. The compounds of the disclosure are highly selective D2 receptor antagonists, useful for treating schizophrenia, depression, bipolar disorder, post-operative nausea or vomiting, Tourette's syndrome, tardive dyskinesia, Huntington's chorea, and gastroesophageal reflux disease. The disclosure also provides pharmaceutical compositions comprising a compound or salt of Formula I.
Resumen de: AU2024283557A1
Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).
Resumen de: MX2025009645A
Provided herein are compounds, phannaceutical compositions, and methods of use for reducing the amount or activity of SNCA mRNA in a cell or subject, and in certain instances reducing the amount of alpha-synuclein protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of a synucleinopathy. Such synucleinopathies include Parkinson's disease, dementia with Lewy bodies (DLB), diffuse Lewy body disease, Parkinson's disease dementia (PDD), pure autonomic failure, multiple system atrophy (MSA), neuronopathic Gaucher's disease, and Alzheimer's disease.
Resumen de: MX2024002080A
The present invention is directed to a method for treating Parkinson's disease. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. Dapansutrile minimizes the clinical features of PD such as locomotor impairments through the modulation of the inflammatory response, reduction in α-synuclein levels, and protection of dopaminergic neurons. A preferred route of administration is oral administration.
Resumen de: MX2025013653A
The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/ Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)ZCoronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.
Resumen de: MX2025014278A
Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).
Resumen de: MX2025014802A
Disclosed herein are methods of selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain based on the risk of an ARIA event or brain hemorrhage. Also disclosed herein are methods of treating subjects having or suspected of having AD comprising subcutaneously administering an anti-Aβ protofibril antibody.
Resumen de: MX2025014083A
Herein is reported a bispecific antibody specifically binding to human Abeta protein and human transferrin receptor (bispecific anti-Abeta/TfR antibody) as well as the use of such bispecific antibodies as a medicament in the treatment of Alzheimer's Disease, including where the bispecific antibody is administered intravenously at a dose of 0.2 mg/kg to 7.2 mg/kg once every four weeks.
Resumen de: MX2025009971A
Provided herein is an anti-CD2 antibody or antigen binding fragment thereof for treating and/or preventing ALS in a subject in need thereof.
Resumen de: GB2642355A
The present disclosure relates to crystalline polymorphs of the compound of Formula (I), namely N-(4-bromo-2,5-difluorophenyl)-6-chloro-1H-pyrrolo2,3-bpyridine-3-sulfonamide: Crystalline forms designated F1, F2, and F3 are provided. Each form is characterized by a distinct X-ray powder diffraction (XRPD) pattern. Form F1 exhibits characteristic 2θ peaks at approximately 7.3, 7.8, 8.1, 12.9, 16.8, 19.8, 25.5, 25.9, 26.2, and 32.3° (± 0.2°). Form F2 exhibits characteristic peaks at approximately 8.1, 14.8, 16.6, 18.8, 19.5, 21.1, 22.6, 26.0, 26.7, and 28.8° (± 0.2°). Form F3 exhibits characteristic peaks at approximately 11.8, 15.2, 15.4, 17.9, 23.8, 24.4, 26.6, 28.3, 28.8, and 30.5° (± 0.2°). Pharmaceutical compositions comprising one of these crystalline forms and one or more pharmaceutically acceptable excipients are also provided. The disclosed crystalline forms and compositions are useful in the treatment or prophylaxis of GPR17-associated diseases, including multiple sclerosis, neuromyelitis optica, and other demyelinating disorders, as well as neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Methods for manufacturing pharmaceutical formulations comprising these crystalline forms are also described.
Resumen de: WO2024182311A2
Disclosed are novel strategies for the treatment of patients with Parkinson's disease and other primary and secondary Parkinsonian disorders by enhancing cell engraftment. Cell viability, engraftment, proliferation, migration, or differentiation of administered DA neuronal cells is enhanced by treating the patient with an antilipemic agent and/or a CSF-1R antagonist before, during and/or after transplantation of DA neuronal cells.
Resumen de: EP4674433A2
Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.
Resumen de: WO2026002277A1
The present invention provides a nucleic acid molecule used for regulating the level or amount of Tau mRNA. Specifically, the present invention provides the delivery of a primary microRNA to form a precursor after in vivo processing, and a microRNA used for the in vivo inhibition of the expression of Tau mRNA. The present invention also provides a delivery system for the nucleic acid molecule, comprising a vector, an exosome and a cell, and a pharmaceutical composition containing same. The present invention also provides an application of the nucleic acid molecule and the delivery system in neurodegenerative disease treatment and drug preparation, in particular a method and a drug targeting Alzheimer's disease.
Resumen de: WO2026006477A1
Among other tilings, the present disclosure provides various technologies including chirally controlled oligonucleotide compositions and technologies for manufacturing and using such oligonucleotide compositions. In some embodiments, the present disclosure provides technologies useful for allele-specific knockdown of mutant Huntingtin transcripts. In some embodiments, the present disclosure provides technologies usefill for reducing the expression, level, amount, and/or activity of mutant Huntingtin transcripts or products thereof. In some embodiments, the present disclosure provides methods for treating Huntington's disease.
Resumen de: KR20260000344A
본 발명은 파킨슨병 치료 효율의 상승을 위한 엑소좀 매개 약물 전달 기술에 관한 것으로서, 본 발명은 신경세포 유래 엑소좀 및 약물 로딩 엑소좀의 특성을 분석하였으며, 약물 로딩 엑소좀이, 파킨슨병 세포 모델에서, 신경세포 사멸을 보호하는 것을 확인하였다. 또한, 파킨슨병 동물모델에서, 운동기능 장애를 개선시키고, 중뇌 신경망의 구조적 완전성을 회복시키며, α-시누클레인의 발현을 감소시켜, 파킨슨병을 개선시키는 것을 확인하였다.
Nº publicación: WO2026006510A1 02/01/2026
Solicitante:
UNIV VIRGINIA COMMONWEALTH [US]
VIRGINIA COMMONWEALTH UNIVERSITY
Resumen de: WO2026006510A1
NOD-like receptor protein 3 (NLRP3) inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using the NSIs to inhibit inflammation and prevent or treat NRLP3 inflammasome dysregulation associated diseases and conditions, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID-19, diabetes, macular degeneration, and autoimmune/autoinflammatory diseases.
BOPI
Sede Electrónica
